FDA Issues Revised Draft Bioequivalence Guidances for Nine Drug Ingredients
July 30, 2026
July 30, 2026
WASHINGTON, July 30 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has announced the availability of revised draft product-specific guidances for nine drug ingredients to assist manufacturers preparing abbreviated new drug applications (ANDAs) and bioequivalence studies for generic medicines.
The notice covers revised draft guidances for products containing calcitonin salmon, dasiglucagon hydrochloride, glucagon, liraglutide, pegcetacoplan, . . .
The notice covers revised draft guidances for products containing calcitonin salmon, dasiglucagon hydrochloride, glucagon, liraglutide, pegcetacoplan, . . .